RMC-5552

N/A

Report date: 2026/04/21 20:00:18
NME

Base Information

Drug NameRMC-5552
Drug Alias NameRMC-5552
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMammalian target of Rapamycin (mTORC1) inhibitorsEukaryotic translation initiation factor 4E inhibitors
TargetsMammalian target of Rapamycin (mTORC1)Eukaryotic translation initiation factor 4E
Therapy Area/IndicationsSolid tumoursGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesRevolution Medicines Inc
China Registration ClassN/A

Develop Information

Active CompaniesRevolution Medicines Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsGlioblastoma

Other Information

ATC CodeN/A
Related LinksN/A